Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

v3.24.1
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Mar. 15, 2024
Document Information [Line Items]    
Document Type 10-K  
Document Annual Report true  
Document Period End Date Dec. 31, 2023  
Document Transition Report false  
Entity File Number 001-36291  
Entity Registrant Name DIAMEDICA THERAPEUTICS INC.  
Entity Incorporation, State or Country Code A1  
Entity Address, Address Line One 301 Carlson Parkway, Suite 210  
Entity Address, City or Town Minneapolis  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55305  
City Area Code 763  
Local Phone Number 496-5454  
Title of 12(b) Security Voting Common Shares, no par value per share  
Trading Symbol DMAC  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Entity Shell Company false  
Entity Public Float $ 103.4  
Entity Common Stock, Shares Outstanding (in shares)   37,958,000
Auditor Firm ID 23  
Auditor Name Baker Tilly US, LLP  
Auditor Location Minneapolis, MN  
Entity Central Index Key 0001401040  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus FY  
Amendment Flag false